Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 795.67 USD -0.08% Market Closed
Market Cap: 755.3B USD
Have any thoughts about
Eli Lilly and Co?
Write Note

Eli Lilly and Co
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Eli Lilly and Co
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Eli Lilly and Co
NYSE:LLY
Accounts Receivables
$10.3B
CAGR 3-Years
20%
CAGR 5-Years
13%
CAGR 10-Years
11%
Johnson & Johnson
NYSE:JNJ
Accounts Receivables
$16.2B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Accounts Receivables
$9.7B
CAGR 3-Years
7%
CAGR 5-Years
18%
CAGR 10-Years
18%
Pfizer Inc
NYSE:PFE
Accounts Receivables
$11.4B
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Accounts Receivables
$11.4B
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
6%
Zoetis Inc
NYSE:ZTS
Accounts Receivables
$1.4B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
3%
No Stocks Found

Eli Lilly and Co
Glance View

Market Cap
755.8B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Eli Lilly and Co. has long been a stalwart in the pharmaceutical industry, sculpting its trajectory through innovation and strategic acumen. Founded in 1876 by Colonel Eli Lilly, the company has grown from a small chemical firm into a global powerhouse in developing life-changing medications. Its headquarters in Indianapolis, Indiana, serve as a hub of research and development, where groundbreaking scientific exploration meets business strategy. Eli Lilly thrives on its core pillars of innovation in oncology, immunology, and diabetes care, relying on a deep commitment to scientific discovery and patient care. This emphasis allows it to consistently bring cutting-edge treatments to market, boosting its reputation as a leader in pharmaceuticals and maintaining a strong pipeline of drugs that drive future growth. The company's business model is principally built around creating proprietary medications that command premium pricing due to their uniqueness and effectiveness. This model sustains Eli Lilly's revenue through a dual approach: serving mature markets with established products and fueling growth with new launches. Patents on flagship drugs protect these revenue streams, allowing the company to invest substantially in research and development, which in recent years prioritizes personalized medicine and biotechnology. Collaborations with academic institutions and other corporations have also been pivotal, accelerating drug development and expanding Eli Lilly's reach across therapeutic areas. Overall, its ability to navigate regulatory frameworks and maintain robust sales and marketing strategies ensures its medications reach patients globally, securing its financial health and influence within the healthcare landscape.

LLY Intrinsic Value
332.78 USD
Overvaluation 58%
Intrinsic Value
Price

See Also

What is Eli Lilly and Co's Accounts Receivables?
Accounts Receivables
10.3B USD

Based on the financial report for Sep 30, 2024, Eli Lilly and Co's Accounts Receivables amounts to 10.3B USD.

What is Eli Lilly and Co's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
11%

Over the last year, the Accounts Receivables growth was 26%. The average annual Accounts Receivables growth rates for Eli Lilly and Co have been 20% over the past three years , 13% over the past five years , and 11% over the past ten years .

Back to Top